Results 141 to 150 of about 319,431 (262)
This study developed a double‐network hydrogel with piezoelectric properties, exhibiting excellent antibacterial activity and promoting fibroblast migration, angiogenesis, and lymphangiogenesis through piezoelectric stimulation, thereby accelerating the healing of infected chronic wounds.
Xiang Li +7 more
wiley +1 more source
Incremental peritoneal dialysis preserves residual renal function in diabetic end-stage kidney disease. [PDF]
Lu L +6 more
europepmc +1 more source
This study establishes [68Ga]Ga‐DOTA‐AP9 as a first‐in‐human CD147‐targeted PET tracer with favorable safety and specific tumor uptake. Tracer accumulation correlates with CD147 expression in patients, enabling noninvasive quantification of CD147‐positive malignancies.
Xiaokun Ma +10 more
wiley +1 more source
First Documented Atrial Fibrillation Triggered by Dialysis-Induced Autonomic Instability in End-Stage Kidney Disease. [PDF]
Kammawal Y, Azmoon M.
europepmc +1 more source
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
Value-Based Model for Vascular Access Management in the End-Stage Kidney Disease Population. [PDF]
Raskin D +5 more
europepmc +1 more source
MDM2 dependency in pediatric sarcomas is driven by a novel p53‐independent oncogenic cistrome alongside canonical p53 pathway suppression. This study introduces MDM2‐recruiting transcriptional and epigenetic machinery degraders (MDM2‐TEMADs) as a novel precision oncology modality.
Jiawei Zhou +21 more
wiley +1 more source
Effect of serum albumin on cardiac-related events in end-stage kidney disease with mitral regurgitation initial hemodialysis. [PDF]
Wang X +7 more
europepmc +1 more source
A multifunctional nanoagonist (cDZ@IP) enables nano‐metabolite–driven multimodal activation of the STING pathway and enhanced immune recognition, achieving potent antitumor immunity and suppressing tumor growth and metastasis. This strategy highlights the rational design of therapeutic metabolites and establishes a new paradigm bridging nanomedicine ...
Kepeng Hu +17 more
wiley +1 more source
A qualitative study examining barriers to buprenorphine for pain management in patients with end stage kidney disease undergoing hemodialysis. [PDF]
Edwards KA +7 more
europepmc +1 more source

